|
Phase I/II Study of Tamoxifen and Tipifarnib to Treat Advanced Breast Cancer Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or treatment with a real dr.. We aren't doctors. Always consult your mD on Phase I/II Study of Tamoxifen and Tipifarnib to Treat Advanced Breast Cancer conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Phase I/II Study of Tamoxifen and Tipifarnib to Treat Advanced Breast Cancer Clinical research trials and Phase I/II Study of Tamoxifen and Tipifarnib to Treat Advanced Breast Cancer medical trials occur in many of places across the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectiveness of new does drugs. The role of the studies / undertakings is to figure out certain human healthcare questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to locate treatments for all forms of circumstances, including Phase I/II Study of Tamoxifen and Tipifarnib to Treat Advanced Breast Cancer. Phase I/II Study of Tamoxifen and Tipifarnib to Treat Advanced Breast Cancer Clinical Trials and other clinical trials permit volunteers to get medical treatment options before they are available to the masses. Most times the human subjects acquire treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a Phase I/II Study of Tamoxifen and Tipifarnib to Treat Advanced Breast Cancer clinical trial. Participants oftentimes recieve the finest healthcare available for their Phase I/II Study of Tamoxifen and Tipifarnib to Treat Advanced Breast Cancer condition. Dangers are a reality, nonetheless, and might include extra or frequent physician calls, health hazards (potentially life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "P" Clinical Trials Conditions > Phase I/II Study of Tamoxifen and Tipifarnib to Treat Advanced Breast Cancer  Phase I/II Study of Tamoxifen and Tipifarnib to Treat Advanced Breast Cancer
Phase I/II Study of Tamoxifen and Tipifarnib to Treat Advanced Breast Cancer
For Condition: Breast Neoplasms
Status: Recruiting
Sponsor(s): National Cancer Institute (NCI) ,
Synopsis: This study will determine the maximum dose of tipifarnib that can be given safely with tamoxifen for patients with advanced (Stage IV) breast cancer and evaluate the effectiveness of the drug combination. Tamoxifen blocks the action of estrogen in some breast cancers and is commonly used to treat this disease, particularly in patients with hormone receptor-positive tumors. Tipifarnib (also known as R115777 or ZARNESTRA) is an experimental drug that is thought to block the signal that tells cancer cells to grow. Patients 18 years of age or older with breast cancer that has recurred or spread beyond the breast may be eligible for this study. Patients must have hormone-receptor positive cancer and have received at least one course of hormonal therapy with either an aromatase inhibitor or estrogen receptor-modulating drug. All participants will receive a standard dose of tamoxifen. They will also receive tipifarnib, but the dose of this drug will vary among patients according to when they enter the study. The first patients will receive a low dose of tipifarnib, and the dose will be increased gradually in subsequent groups of patients as long as it does not cause unacceptable side effects. Once the optimum dose of tipifarnib in combination with tamoxifen is determined, the rest of the patients in the study will receive that dose. Patients will take the drugs in 28-day treatment cycles. They will take tipifarnib twice a day by mouth on days 1 through 21 of each cycle. On day 8 of the first cycle they will start taking tamoxifen and will continue taking this drug by mouth once a day every day for the duration of the study. In addition to drug therapy, patients will undergo the following tests and procedures: -Medical history, physical examination and blood tests before starting treatment, and possibly a chest x-ray, CT scans, bone scans, or mammograms. -Biopsies of tumors where the cancer has spread beyond the breast. T hese will be done before starting therapy, after 1 week of tipifarnib, and at some point after combination treatment with tipifarnib and tamoxifen. -Blood tests at least once a month, plus two studies to measure the amount of tipifarnib and tamoxifen in the blood. The latter studies will be done one day during the first week of therapy and one day during the second month of therapy and may require an overnight hospital stay. For each study, blood will be drawn 14 times within 12 hours at intervals of 30 minutes to 4 hours. If possible, an indwelling catheter will be placed in an arm vein to obtain the blood samples without multiple needle sticks. -CT scans and bone scans after 2 and 4 months of therapy to evaluate the cancer's response to treatment. Patients whose disease worsens with treatment will stop the drugs and be advised of other options. Those in whom the tumor remains stable, or shrinks, and who do not have severe drug side effects, may continue treatment indefinitely as long as tipifarnib is available and there is no disease progression or serious side effects.
Details: This is a phase I/II trial to determine acute and chronic toxicity of tipifarnib (R115777, ZARNESTRA) in combination with the standard dose of tamoxifen (20 mg po daily) and to identify a tolerable chronic dose for phase II testing. The phase II portion of the study will determine response rate in patients who have experienced a disease recurrence after prior hormonal therapy and evaluate drug effects on biomarkers.
Eligibility:
Study Type: Interventional, Treatment, Safety
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: INCLUSION CRITERIA: Phase II -ARM 1: Homone Responsive: Subjects must have a diagnosis of metastatic (Stage IV) breast cancer with evidence of disease progression. If available, pathologic or cytological material will be reviewed at the NIH CC Laboratory of Pathology. Subjects must have ER and/or PR positive breast cancer. As few as 1% ER or PR positive cells will be considered hormone receptor positive. Subjects must be 18 years of age or older. Subjects must have received no chemotherapy for at least 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to initiating investigational therapy. Subjects must have been treated with at lest one prior hormonal therapy with either an aromatase inhibitor or an estrogen receptor-modulating drug either in the adjuvant or metastatic setting. Subjects must have a history of either stable disease (no recurrence or progression) for greater than or equal to 6 months or an objective response with a prior hormonal therapy. Subjects may have received tamoxifen. However, at least 6 months must have elapsed since prior tamoxifen therapy. Subjects must have measurable disease as defined further in the protocol. Subjects must have no evidence of CNS metastases. Subjects must have had no more than two prior chemotherapy regimens for metastatic disease (there are no limitations on prior neoadjuvant or adjuvant chemotherapy regimens). Subjects must have recovered from the effects of prior therapy with resolution of any toxicities to less than or equal to grade 1. Performance Status of Zubrod 0-1 Female subjects of child-bearing potential and male subjects and male partners of female subjects must be willing to use effective non-hormonal contraception while receiving study drugs and for 2 months thereafter. Subjects must be willing to provide written informed consent. INCLUSION CRITERIA: Phase II - Arm 2: Hormone Unresponsive: Subjects must have a diagnosis of metastatic (Stage IV) breast cancer with evidence of disease progression. If available, pathologic or cytological material will be reviewed at the NIH CC Laboratory of Pathology. Subjects must have ER and or PR positive breast cancer. As few as 1% ER or PR positive cells will be considered hormone receptor positive. Subjects must be 18 years of age or older. Subjects must have received no chemotherapy for at least 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to initiating investigational therapy. Subjects must have been treated with at lest one prior hormonal therapy with either an aromatase inhibitor or an estrogen receptor-modulating drug either in the adjuvant or metastatic setting. Subjects must have NO history of either stable disease (no recurrence or progression) for greater than or equal to 6 months or an objective response with a prior hormonal therapy. Subject may have received tamoxifen. However, at least 6 months must have elapsed since prior tamoxifen therapy. Subjects must have measurable disease as defined further in the protocol. Subjects must have no evidence of CNS metastases. Subjects must have had no more than two prior chemotherapy regimens for metastatic disease (there are no limitations on prior neoadjuvant or adjuvant chemotherapy regimens). Subjects must have recovered from the effects of prior therapy with resolution of any toxicities to less than or equal to grade 1. Performance Status of Zubrod 0-1 Female subjects of child-bearing potential and male subjects and male partners of female subjects must be willing to use effective non-hormonal contraception while receiving study drugs and for 2 months thereafter. Subjects must be willing to provide written informed consent. EXCLUSION CRITERIA: Subjects with an absolute neutrophil count of less than 1500/(micro)L Subjects with a platelet count of less than 100,000/(micro)L Subjects with no evidence of disease Subjects who have any medical or psychiatric condition that in the opinion of the Principal Investigator would preclude them from participating in this study Subjects with a SGOT and SGPT greater than or equal to 3 times the upper limit of normal unless there is liver involvement by tumor. Subjects with a total bilirubin greater than 2.0 unless there is clinical evidence of Gilbert's disease. Subjects with a creatinine of greater than 1.5 mg/dL. Subjects with CNS metastases. Subjects taking cytochrome p450-inducing anticonvulsants. Subjects taking warfarin. Subjects who are pregnant.
Total Enrollment: 52
Location and Contact Information:
National Cancer Institute (NCI) *Recruiting*
Bethesda, Maryland, 20892
United States
Recruiting Patient and Public Liaison Office 1-800-411-1222
Additional Information:
Study ID Numbers: 030037; 03-C-0037
Study Start Date: November 5, 2002
Record last reviewed: August 19, 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00048867
Other Breast Neoplasms Studies:
1. Study of Motexafin Gadolinium and Docetaxel for Advanced Solid Tumors
2. Comparison of Nolvadex 20 mg and placebo combination to Nolvadex 20 mg and ZD1839 (IRESSA™) 250 mg combination in patients with metastatic breast cancer and estrogen receptor (ER) and/or progesterone (PR) positive tumours
3. Evaluation of Bay 59-8862 in Taxane-Resistant Metastatic Breast Cancer Patients
4. Study of ABI-007 and Taxol in Patients with Metastatic Breast Cancer
5. Zometa - Femara Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women with Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy
Related Studies:
Other Breast Neoplasms Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Phase I/II Study of Tamoxifen and Tipifarnib to Treat Advanced Breast Cancer
|
|
|
|
|
|
|
|
